Tech Company Financing Transactions
Nalagenetics Funding Round
On 3/25/2022, Nalagenetics landed $12.6 million in Series A financing from Intudo Ventures and Vulcan Capital.
Transaction Overview
Company Name
Announced On
3/25/2022
Transaction Type
Venture Equity
Amount
$12,600,000
Round
Series A
Investors
Intudo Ventures (Lead Investor)
Vulcan Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to focus on product development for CDS to enable whole genome analysis and integration with more providers and hospitals, and increase headcount with an emphasis on bioinformatics, software engineering, and genetics experts.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
1093 Lower Delta Road, #04-05/06/07/08,
Singapore, 169204
Singapore
Singapore, 169204
Singapore
Phone
Website
Email Address
Not Recorded
Overview
Operator of a personalized prescription platform designed to offer accurate testing, impactful outcomes and localized recommendations. The company's platform increases prescription efficacy through genetic testing and information management systems, enabling patients and decision-makers to have access to personalized information on how to interact with existing healthcare technologies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Levana Sani
Chief Operating Officer
Astrid Irwanto
Co-Founder
Alexander Lezhava
Co-Founder
Jianjun Liu
Browse more venture capital transactions:
Prev: 3/25/2022: EdgeCortix venture capital transaction
Next: 3/25/2022: Geneos Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs